Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sistemic Announces Customer Agreement with Cytori

Published: Wednesday, June 20, 2012
Last Updated: Wednesday, June 20, 2012
Bookmark and Share
Cytori to utilize Sistemic’s SistemQC™ to strengthen understanding of mechanisms & support design of next-generation cell therapies.

Sistemic Ltd. has formed a customer relationship with Cytori Therapeutics (“Cytori”). Cytori will utilize Sistemic’s proprietary SistemQC™ technology platform in its U.S. cardiac cell therapy clinical trial to molecularly characterize adipose-derived stem and regenerative cells (ADRCs).

“Research has shown that within adipose tissue, as well as other cell sources like bone marrow, there are multiple distinct cell types that can contribute to efficacy,” commented Sistemic chairman and CEO Jim Reid.

Reid continued, “Cytori selecting our SistemQC serves as another validation of our technology, particularly its flexibility to characterize a wide variety of cells for identity and potency, on a molecular level. We could not be more pleased to have reached this agreement with Cytori.”

The announcement was made at the 2012 Bio International Convention in Boston, where Mr. Reid is moderating a panel on stem cell therapeutics featuring leaders from the industry, on Wednesday, June 20, at the Boston Convention Center.

“SistemQC will be incorporated into our clinical development to understand which cell types within our Celution® System’s autologous heterogeneous population of ADRCs are the greatest contributors to efficacy,” said Douglas Arm, Ph.D., Senior Vice President Operations at Cytori.

Arm continued, “With Sistemic’s novel technology, we can strengthen the mechanistic understanding of our cell output and at the same time support the design of next-generation cell therapies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement
Agreement to advance miRNA and mesenchymal stem/stromal cell (MSC) regenerative technology.
Tuesday, June 02, 2015
Sistemic, RoosterBio Collaborate
This is a collaboration and memorandum of understanding to combine their technologies to advance mesenchymal stem/stromal (MSC) regenerative technology.
Friday, May 29, 2015
Sistemic to Work with TiGenix On Landmark EUR 5.9 Million, FP7 European Project
The collaboration aims at developing an innovative rheumatoid arthritis cell therapy treatment product.
Tuesday, February 07, 2012
Rapid Growth Continues for Sistemic
Company is relocating to customized laboratories during the first half of 2012.
Thursday, January 19, 2012
Sistemic Join the Alliance for Regenerative Medicine
ARM to advance regenerative medicine by representing and supporting members in front of government agencies and the general public.
Friday, December 30, 2011
Sistemic Highlights the Need for Better Cell Characterization in Regenerative Medicine
Dr Verna McErlane took part in a round-table discussion with stem cell researchers.
Thursday, December 29, 2011
How to Progress Safe and Effective Cell Therapies for Clinical Use!
Sistemic to present miRNA-led cell characterization at Stem Cell Europe.
Tuesday, July 19, 2011
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Defining Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
Topical Immunotherapy Effective Against Early Skin Cancer
Combination of two commonly used drugs triggers immune response against precancerous skin lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!